Although results have not yet been published, a phase 3 trial comparing the IDH2 inhibitor enasidenib with a variety of conventional care regimens in patients with IDH2-mutant AML after failure of two or three lines of prior therapy did not meet its primary endpoint of OS69. The gene discussed is IDH2; the disease is acute myeloid leukemia.